sulinotropic actions of exendin-4 andglucagon-like peptide-1 in vivo  and in vitro . Metabolism . 2001; 50:583-9. 13. Szayna M, Doyle ME, Betkey JA et al. Exendin-4 decelerates food intake, weightgain, and fat deposition in Zucker rats.Endocrinology.  2000; 141:1936-41. 14. Nielsen LL, Baron AD.  Pharmacology of exenatide (synthetic exendin-4) for thetreatment of type 2 diabetes. Curr Opin Investig Drugs . 2003; 4:401-5. 15. Xu G, Stoffers DA, Habener JF et al. Exendin-4 stimulates both  β-cell replica- tion and neogenesis, resulting in in-creased  β-cell mass and improved glucose tolerance in diabetic rats. Diabetes.  1999; 48:2270-6. 16. Tourrel C, Bailbé D, Lacorne M et al. Persistent improvement of type 2 diabe-tes in the Goto-Kakizaki rat model byexpansion of the  β-cell mass during the prediabetic period with glucagon-likepeptide-1 or exendin-4. Diabetes.  2002; 51:1443-52. 17. Tourrel C, Bailbé D, Meile MJ et al. Glucagon-like peptide-1 and exendin-4stimulate